Last reviewed · How we verify
Tiotropium (SpirivaTM)
Tiotropium (SpirivaTM) is a Long-acting muscarinic antagonist (LAMA) Small molecule drug developed by AstraZeneca. It is currently FDA-approved for Chronic obstructive pulmonary disease (COPD) maintenance treatment, Asthma (in combination with inhaled corticosteroids).
Tiotropium is a long-acting anticholinergic (muscarinic antagonist) that blocks M3 receptors on airway smooth muscle to produce sustained bronchodilation.
Tiotropium (SpirivaTM) is a medication used to treat Chronic Obstructive Pulmonary Disease (COPD). It is a bronchodilator that works by blocking the action of acetylcholine at muscarinic receptors in the lungs, as indicated by its listing in ChEMBL.
At a glance
| Generic name | Tiotropium (SpirivaTM) |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Long-acting muscarinic antagonist (LAMA) |
| Target | M3 muscarinic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Tiotropium binds to muscarinic M3 receptors on airway smooth muscle cells, preventing acetylcholine-induced bronchoconstriction. This produces a prolonged bronchodilatory effect lasting 24 hours or more, allowing once-daily dosing. The drug is delivered via inhalation directly to the lungs, minimizing systemic exposure.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance treatment
- Asthma (in combination with inhaled corticosteroids)
Common side effects
- Dry mouth
- Tremor
- Headache
- Sinusitis
- Urinary retention
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tiotropium (SpirivaTM) CI brief — competitive landscape report
- Tiotropium (SpirivaTM) updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about Tiotropium (SpirivaTM)
What is Tiotropium (SpirivaTM)?
How does Tiotropium (SpirivaTM) work?
What is Tiotropium (SpirivaTM) used for?
Who makes Tiotropium (SpirivaTM)?
What drug class is Tiotropium (SpirivaTM) in?
What development phase is Tiotropium (SpirivaTM) in?
What are the side effects of Tiotropium (SpirivaTM)?
What does Tiotropium (SpirivaTM) target?
Related
- Drug class: All Long-acting muscarinic antagonist (LAMA) drugs
- Target: All drugs targeting M3 muscarinic receptor
- Manufacturer: AstraZeneca — full pipeline
- Therapeutic area: All drugs in Respiratory
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD) maintenance treatment
- Indication: Drugs for Asthma (in combination with inhaled corticosteroids)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing